Leukotriene D4 bronchial provocation test: methodology and diagnostic value
Authors:
- 1 May 2012
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 28 (5) , 797-803
Abstract
Although leukotriene D4 (LTD4) is a potent bronchoconstrictor, little is known about airway responsiveness to LTD4 in asthmatics with different inflammation phenotypes. To establish the methodology and investigate the distribution characters of airway responsiveness, diagnostic value and safety of LTD4 bronchial provocation test. LTD4 bronchial provocation tests were performed in 62 asthmatics and 21 normal controls. Airway responsiveness was assessed based on the cumulative dosage causing a 20% fall in FEV1 (PD20FEV1-LTD4) and was expressed as (median, interquartile range). The fall in spirometric parameters was plotted showing the distribution characters. The diagnostic value was assessed using receiver operation characteristic (ROC) curve. All adverse events were recorded during the test. Airway responsiveness to LTD4 was significantly higher in asthmatics (0.410 nmol, 0.808 nmol) as compared with normal controls (5.00 nmol, 0.00 nmol). The decrease in spirometric parameters varied after bronchoprovocation, which was negatively correlated with PD20FEV1-LTD4, among which FEV1 had a maximal slope (r = −0.524, P = 0.000). High diagnostic value (AUC: 0.914, 95%CI: [0.855, 0.974]) was revealed by ROC curve. The major adverse events were dyspnea (82.3%), chest tightness (72.6%), wheezing (32.3%) and coughing (25.8%) in asthmatics, which could overall be recovered within 15.0 minutes after inhalation of 200 ∼ 400 mcg salbutamol MDI. No serious adverse event was reported. The established procedure of LTD4 bronchial provocation test is effective in the diagnosis of asthma and is well tolerated. Future studies are necessary to provide more evidences in terms of safety and efficacy. This may be helpful upon further application in clinical practice.Keywords
This publication has 23 references indexed in Scilit:
- Montelukast for the treatment of asthma in the adult populationExpert Opinion on Pharmacotherapy, 2011
- Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller TrialJournal of Allergy and Clinical Immunology, 2011
- An update on the role of leukotrienes in asthmaCurrent Opinion in Allergy and Clinical Immunology, 2010
- Leukotriene E4: Perspective on the forgotten mediatorJournal of Allergy and Clinical Immunology, 2009
- Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionateJournal of Allergy and Clinical Immunology, 2006
- The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in AsthmaChest, 2001
- Leukotrienes as Mediators of Airway ObstructionAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Leukotrienes in the Pathogenesis of AsthmaChest, 1997
- The reproducibility and effect on non‐specific airway responsiveness of inhaled prostaglandin D2 and leukotriene D4 in asthmatic subjects.British Journal of Clinical Pharmacology, 1995
- Potent Leukotriene D4 Receptor Antagonist ICI 204/219 Given by the Inhaled Route Inhibits the Early but not the Late Phase of Allergen-induced BronchoconstrictionAmerican Review of Respiratory Disease, 1993